The Study of Genetic Testing from Your Living Room.
The MAGENTA study aims to improve availability of genetic testing for hereditary cancer syndromes to at-risk individuals through the use of an online genetic testing service. Our hope is that making genetic testing accessible, without requiring them to travel to their healthcare provider, will save more lives by preventing cancer in women found to be at an increased risk of getting it.
Complete the eligibility questionnaire to find out if you are eligible for our study
Participation in this trial will not require any travel, but will require access to the internet and phone.
Participants who qualify for this study will fill out personal and family health history information, undergo genetic testing (saliva sample) for 19 genes associated with inherited cancer risk *, and complete a series of online questionnaires regarding their experience. Some individuals in this study will undergo genetic counseling over the phone; others not. For more information on study requirements, please review the MAGENTA Study Timeline below.
* The 19-gene panel includes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MSH2, MSH6, MLH1, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, and STK11.
- Color Genomics owns and operates a CLIA licensed and CAP-accredited laboratory in California, U.S.A. that will be performing the genetic testing.
- All participants with a positive test result will receive genetic counseling over the phone.
A Collaborative Research Effort
The MAGENTA study is supported by the Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team.